# GSK plc American (GSK) fundamentals

Data as of 2026-09-08. NYSE, United States. Sector: Healthcare / Pharmaceuticals. Price $49.89, market value $99.9 billion.

## Valuation
- **P/E (trailing): 15.7×** (5-yr avg 31.3×, 3-yr avg 38.0×). GSK plc American trades at 15.7× trailing earnings, well below its own five-year average of 31.3×: cheap by its own standards. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 10.0×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 0.08**. A PEG of 0.08 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 2.2×**. Each dollar of revenue is priced at 2.2×.
- **Price / book: 4.2×**. The shares trade at 4.2× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 8.7×**. Enterprise value is 8.7× operating earnings before depreciation, the multiple that ignores how the company is financed.
- **Free-cash-flow yield: 7.2%** (5-yr avg 4.2%). Free cash flow equals 7.2% of the market value, above its five-year average of 4.2%, so the shares are cheaper on cash than they have usually been. Above 5% is generally attractive.
- **Earnings yield: 6.4%**. The inverse of the P/E: 6.4% of the price is earned each year.

## Profitability
- **Gross margin: 72.7%**. GSK plc American keeps 72.7% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: 20.7%**. 20.7% of revenue is left after running the business, a healthy level in most sectors.
- **Net margin: 19.3%**. 19.3% of each dollar of sales reaches the bottom line.
- **Return on equity: 39.4%**. 39.4% on shareholders' equity is excellent if it is not driven by leverage; sustained above 20% usually signals a competitive advantage.
- **Return on invested capital: 20.2%**. Return on all capital, debt included, is 20.2%: comfortably above what that capital costs.
- **Return on assets: 7.9%**. Each dollar of assets produces 7.9% of profit.

## Growth
- **Revenue growth (1 yr): 4.1%** (3-yr 3.7%/yr, 5-yr 6.0%/yr). Revenue grew 4.1% over the last year, against 6.0% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): 124.2%** (3-yr -27.6%/yr, 5-yr -0.6%/yr). Earnings per share rose 124.2%, faster than revenue, so margins expanded or the share count shrank.
- **Free-cash-flow growth (3 yr): 0.7%/yr**. Free cash flow has compounded at 0.7% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Debt to equity: 1.11**. Debt is 1.11 times equity, a leveraged balance sheet that needs steady cash flow to service.
- **Net debt / EBITDA: 1.4×**. It would take 1.4 years of operating earnings to repay net borrowings, within the comfortable range.
- **Interest coverage: 10.0×**. Operating profit covers interest 10.0× over, a safe margin.
- **Altman Z-score: 2.66**. A Z-score of 2.66 is in the grey zone; not distressed, not clearly safe.
- **Piotroski F-score: 8/9**. 8 of 9 fundamental checks pass: strong and improving financials.

## Dividends
- **Dividend yield: 3.64%** ($1.82 per share, trailing). GSK plc American yields 3.64%, an income-level yield.
- **Payout ratio: 41%** (50% of free cash flow). 41% of earnings goes out as dividends, leaving room to keep raising it.
- **Consecutive years of increases: 2**. 2 straight years of increases.
- **Dividend growth (5 yr): -4.0%/yr** (1-yr 7.6%). The dividend has not grown over five years.
- **Shareholder yield: 5.3%**. Dividends plus net buybacks return 5.3% of the market value a year.

## Analyst view
- **Analyst consensus: hold** (8 analysts). 8 analysts cover GSK plc American; the consensus is hold, with an average price target of $58.58 (+17% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 29.2%** (YTD 3.5%, 3-mo -3.2%). The shares are up 29.2% over twelve months including dividends.
- **From 52-week high: -19.1%** (27.0% above the low). Trading 19% below its 52-week high.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 43**. An RSI of 43 is neutral.
- **Beta (1 yr): 0.27** (volatility 27%). Beta of 0.27 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=GSK · Page: https://foliofundamentals.com/stocks/gsk

Not investment advice.